The Institut de Recherche pour le Développement, Délégation Régionale Occitanie (IRD-Montpellier), and NeoVentures Biotechnology Europe (NVBE) are proud to announce a strategic partnership to co-develop the NVBE Aptamarker platform for single-cell proteomics. This collaboration combines cutting-edge technology with world-class expertise to advance research in infectious diseases.

The Institut de Recherche pour le Développement (IRD) is the French National Research Institute for Sustainable Development. It is a globally recognized multidisciplinary organization that works closely with developing countries, particularly in intertropical regions and the Mediterranean. IRD has a long history of driving innovative research in biology, health, and environmental sciences. Dr. Arthur Talman, an internationally renowned researcher, leads pioneering work in applying transcriptomics to infectious disease agents. His expertise provides critical insight for the partnership’s focus on malaria research.

The first collaborative project will apply the Aptamarker platform to study single-cell proteomics in Plasmodium falciparum, the parasite responsible for malaria. Specifically, the project will investigate the molecular mechanisms involved in sexual reproduction and transmission of the parasite. By leveraging the Aptamarker platform, researchers will gain unprecedented insight into protein states at the single-cell level.

The Aptamarker platform offers a high-plex proteomics approach, enabling comprehensive coverage across diverse species samples. Unlike traditional methods, it directly characterizes proteins in their native cellular context. This allows researchers to uncover functional changes and interactions that drive disease processes.

Through this partnership, IRD-Montpellier and NVBE aim to accelerate scientific discovery, enhance understanding of malaria transmission, and demonstrate the power of the Aptamarker platform in cutting-edge proteomics research. This collaboration sets the stage for future projects applying animal-free, high-resolution biomarker discovery to global health challenges.

To keep up-to-date with NeoVentures, check out our LinkedIn profile or our events page here.